Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aslan Pharmaceuticals Ltd ADR (ASLN)
NASDAQ:ASLN
RESEARCH TOOLSreports
Holding ASLN?
Track your performance easily
ASLN Stock Chart & Stats
Day’s Range$0.6 - $0.7
52-Week Range― - ―
Previous Close$0.7
Volume806.35K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.50Price Target Upside1483.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aslan Pharmaceuticals News
PremiumCompany Announcements
Aslan Pharmaceuticals Begins Voluntary Liquidation
PremiumCompany Announcements
ASLAN Pharmaceuticals Faces Nasdaq DelistingBulls Say, Bears Say
Bulls Say
Clinical Study ResultsASLAN Pharmaceuticals has announced positive interim data from the TREK-DX study, showcasing eblasakimab's strong efficacy and safety profile, which could position it as a leading long-term treatment option for atopic dermatitis patients.
Drug EfficacyPatients treated with eblasakimab experienced a rapid onset of action and a significant reduction in Eczema Area and Severity Index (EASI) score from baseline, indicating a potential new effective treatment for atopic dermatitis.
Market OpportunityWith over 60% of dupilumab-treated patients failing to achieve an IGA score of 0 or 1 after 16 weeks, eblasakimab presents a significant market opportunity as an alternative treatment for atopic dermatitis.
Bears Say
Capital RequirementDue to the company’s near-term capital requirement and current share price, the discount rate was increased from 15% to 18%.
Financial PerformanceNet loss totaled $44.2M in 2023.
Future OutlookClinical catalysts are expected in 2024.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASLN FAQ
What was Aslan Pharmaceuticals Ltd ADR’s price range in the past 12 months?
Currently, no data Available
What is Aslan Pharmaceuticals Ltd ADR’s market cap?
Currently, no data Available
When is Aslan Pharmaceuticals Ltd ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aslan Pharmaceuticals Ltd ADR’s earnings last quarter?
Currently, no data Available
Is Aslan Pharmaceuticals Ltd ADR overvalued?
According to Wall Street analysts Aslan Pharmaceuticals Ltd ADR’s price is currently Undervalued.
Does Aslan Pharmaceuticals Ltd ADR pay dividends?
Aslan Pharmaceuticals Ltd ADR does not currently pay dividends.
What is Aslan Pharmaceuticals Ltd ADR’s EPS estimate?
Aslan Pharmaceuticals Ltd ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aslan Pharmaceuticals Ltd ADR have?
Currently, no data Available
What happened to Aslan Pharmaceuticals Ltd ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aslan Pharmaceuticals Ltd ADR?
Among the largest hedge funds holding Aslan Pharmaceuticals Ltd ADR’s share is Platinum Investment Management. It holds Aslan Pharmaceuticals Ltd ADR’s shares valued at N/A.
---
Aslan Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (1483.33% Upside)
$9.50 (1483.33% Upside)
Hedge Fund Trend
Decreased
By 3.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-65.20%
Trailing 12-Months
Company Description
Aslan Pharmaceuticals Ltd ADR
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm's portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.
---
ASLN Stock 12 Month Forecast
Average Price Target
$9.50
▲(1483.33% Upside)
Technical Analysis
Best Analysts Covering ASLN
1 Year
1 Year Success Rate
3/22 ratings generated profit
1 Year Average Return
-57.70%
reiterated a buy rating 6 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 13.64% of your transactions generating a profit, with an average return of -57.70% per trade.
---